SPTLC2 and Alzheimer disease: Although current research directly involving SPTLC2, AMD1, and IGSF3 in the aforementioned pathways remains relatively limited, the findings strongly suggest that these hub genes might affect the overall metabolic balance of sphingolipids by regulating their synthesis, degradation, and signal transduction processes, ultimately influencing the course of AD.